Heterogeneity of melanoma antigen 1 (MAGE-1) gene and protein expression in malignant melanoma

European Surgical Research

Volumn 29, Issue 5, 1997, Pages 403-410

  Zuber, M ^a,b   Spagnoli, G C ^b   Kocher, T ^a,b   Luscher U ^a,b   Schaefer, C ^b   Noppen, C ^b   Gudat, F ^c   Harder, F ^a,b   Heberer, M ^a,b  

^a Department of Surgery ^*  (Switzerland)

^b Ludwig Institute for Cancer   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Heterogeneity; MAGE 1; Melanoma

Indexed keywords

GENE PRODUCT; MELANOMA ANTIGEN; MESSENGER RNA; MONOCLONAL ANTIBODY;

ARTICLE; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; GENETIC HETEROGENEITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY;

EID: 0030884273     PISSN: 0014312X     EISSN: 14219921     Source Type: Journal    
DOI: 10.1159/000129550     Document Type: Article

References (17)

1. Van der Bruggcn P, Traversari C, Chomez P, Lurquin C, Dc Plaen E, Van den Eynde B, Knuth A, Boon Th: A gene encoding an antigen recognized by cytolytic lymphocytes on a human melanoma. Science 1991; 254:1643-1647.
2. Brasseur F, Marchand M, Vanwijk R, Herin M, Lethe B, Chomez P, Boon Th: Human MAGE-1, which codes for a tumor rejection antigen, is expressed by some breast tumors. Int J Cancer 1992;52:839-841.
3. Eura M, Ogi K, Chikamatsu K, Na-kano K, Masuyama K, Itoh K, Ishi-kawa T: Expression of the MAGE gene family in human hcad-and-neck squamous-cell carcinomas. Int J Cancer 1995;64:304-308.
4. Weynants P, Lethe B, Brasseur F, Marchand M, Boon Th: Expression of MAGE genes by non-small-ccll lung carcinomas. Int J Cancer 1994; 56:826-929.
5. Takahashi K, Shichijo S, Noguchi M, Hirohata M, Itoh K: Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res 1995;55:3478-3482.
6. Schultz-Thater E, Juretic A, Della-bona P, Liischcr U, Sicgrist W, Harder F, Heberer M, Zuber M. Spagnoli GC: MAGE-1 gene product is a cytoplasmic protein. Int J Cancer 1994;59:435-439.
7. Seed B, Aruffo A: Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immuno-selection procedure. Proc Natl Acad Sci USA 1987;84:3365-3369.
8. Liischer U, Filgucira L, Juretic A, Zuber M, Liischer N, Heberer M, Spagnoli GC: The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor infiltrating lymphocytes. Int J Cancer 1994;57:612-619.
9. McLean I, Nakane PK: Periodate-lysinc-paraformaldehyde fixative -A new fixative for immunoelectron microscopy. J Histochem Cytochcm 1974;22:1077-1083.
10. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, Canon JL, Laurent C, Nacyaert JM, Plagne R, Derae-maeker R, Knuth A, Jager E, Brasscur F, Herman J, Coulic PG, Boon Th: Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995:63:883-885.
11. Rammcnscc H-G: Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol 1995;7:85-96.
12. Germain RH, Margulies DH: The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 1993; 11:403-423.
13. Boon T: Tumor antigens and perspectives for cancer immunotherapy. Immunologist 1995:3:262-263.
14. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yanelli JR, Appella E, Rosenberg S: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restrictcd tumor infiltrating lymphocytes. J Exp Med 1994;180:347-352.
15. Burrows SR, Fernan A, Argaet V, Suhrbier A: Bystander apoptosis induced by CD8+ cytotoxic T cell (CTL) clones: Implications for CTL lytic mechanisms. Int Immunol 1993;5:1049-1058.
16. Jager E, Ringhoficr M, Dicnes HP, Arand M, Karbach J, Jager D, Ilse-mann Ch, Hagedorn M, Oesch F, Knuth A: Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 1996:67:54-62.
17. Jager E, Bernhard H, Romero P, RinghotTcr M, Arand M, Karbach J, Ilsemann Ch, Hagedorn M, Knuth A: Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 1996;66:162-169.